验证一种易于实施的算法以界定性传播感染门诊患者青霉素过敏状态的多中心随机试验
该多中心随机试验在性传播感染门诊评估青霉素过敏评估的可行性与安全性。284名自报青霉素过敏者中72人(25.3%)被判定为高风险并排除,206名低风险者分别接受青霉素皮试后阿莫西林250 mg激发或阿莫西林25 mg后250 mg分级口服激发;195人(94.7%)成功完成研究,11人(5.3%)出现轻微症状;作者认为该问卷可安全识别适合评估的患者,67%自报过敏者可安全接受一线治疗。
要点
- 284名自报青霉素过敏者中72人(25.3%)被判定为高风险并排除。
- 206名低风险者中,102人(49.5%)接受青霉素皮试无反应,口服激发时3人(3%)出现轻微反应。
- 104名接受分级口服激发者中95人(91.3%)无反应完成,25 mg后4人(4.2%)、250 mg后4人(4.2%)出现轻微症状。
核心结论
- 易于实施的风险评估问卷可安全识别性传播感染门诊中适合接受青霉素皮试或分级口服激发评估的患者,分级口服激发显示操作可行性。
- 采用该方法,67%自报青霉素过敏的参与者可安全接受淋病或梅毒的一线治疗。
研究设计与样本
- 随机对照试验,评估性传播感染门诊中青霉素过敏评估的可行性与安全性,注册号ClinicalTrials.gov(NCT04620746)。
- 自报青霉素过敏的参与者回答专家制定的问卷以进行风险分层,低风险者接受青霉素皮试后阿莫西林250 mg激发,或接受阿莫西林25 mg后250 mg的分级口服激发。
- 共284名参与者,其中72人(25.3%)被判定为高风险并排除,206名低风险参与者纳入后续评估。
主要发现
- 206名低风险参与者中,102人(49.5%)接受青霉素皮试无反应,口服激发时3人(3%)出现轻微反应。
- 104名(50.5%)参与者接受分级口服激发,其中95人(91.3%)无反应完成激发,4人(4.2%)在25 mg后出现轻微症状,4人(4.2%)在250 mg剂量后出现轻微症状。
- 总体195名参与者(94.7%)成功完成研究,11人(5.3%)出现轻微症状。
- 14名提供者中12人(85.7%)完成调查,其中11人(93%)认同在性传播感染门诊进行青霉素过敏评估的安全性/有效性。
临床怎么用
- 作者认为,易于实施的风险评估问卷可安全识别性传播感染门诊中适合接受青霉素皮试或分级口服激发评估的患者,分级口服激发显示操作可行性。
- 作者指出,采用该方法,67%自报青霉素过敏的参与者可安全接受淋病或梅毒的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 15% of patients in sexually transmitted infection (STI) clinics report penicillin allergies, complicating treatment for syphilis and gonorrhea. Nonetheless, >90% do not have a penicillin allergy when evaluated. We developed and validated an algorithm to define which patients reporting penicillin allergy can be safely treated at STI clinics with these drugs. METHODS: Randomized controlled trial to assess feasibility and safety of penicillin allergy evaluations in STI clinics. Participants with reported penicillin allergy answered an expert-developed questionnaire to stratify risk. Low-risk participants underwent penicillin skin testing (PST) followed by amoxicillin 250 mg challenge or a graded oral challenge (GOC)-amoxicillin 25 mg followed by 250 mg. Reactions were recorded, and participant/provider surveys were conducted. RESULTS: Of 284 participants, 72 (25.3%) were deemed high risk and were excluded. Of 206 low-risk participants, 102 (49.5%) underwent PST without reactions and 3 (3%) had mild reactions during the oral challenge. Of 104 (50.5%) participants in the GOC, 95 (91.3%) completed challenges without reaction, 4 (4.2%) had mild symptoms after 25 mg, and 4 (4.2%) after 250-mg doses. Overall, 195 participants (94.7%) successfully completed the study and 11 (5.3%) experienced mild symptoms. Of 14 providers, 12 (85.7%) completed surveys and 11 (93%) agreed on the safety/effectiveness of penicillin allergy assessment in STI clinics. CONCLUSIONS: An easy-to-administer risk-assessment questionnaire can safely identify patients for penicillin allergy evaluation in STI clinics by PST or GOC, with GOC showing operational feasibility. Using this approach, 67% of participants with reported penicillin allergy could safely receive first-line treatments for gonorrhea or syphilis. Clinical Trials Registration. Clinicaltrials.gov (NCT04620746).
引用
- Lillis RA, Barbee LA, McNeil CJ, et al. Randomized Multicenter Trial for the Validation of an Easy-to-Administer Algorithm to Define Penicillin Allergy Status in Sexually Transmitted Infection Clinic Outpatients. Clin Infect Dis. 2024. PMID: 38325290. doi:10.1093/cid/ciae064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。